Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab

This is a observational study prospectively followed post-authorization.

Inclusion criteria

• Patients should sign inform consent before inclusion in the study that specifies that the clinical treatment entails consent for the analysis of biological samples of tumor and blood.
• Histologically confirmed diagnosis of advanced non small-cell lung carcinoma, non-squamous cell
• Patients age 18 years or more
• Patients will be candidates to received a first line of chemotherapy of carboplatin, paclitaxel and bevacizumab as the best therapeutic option.
• Evidence of measurable disease per Response Evalutation Criteria in Solid tumors (RECIST)
• Patients must be avalaible for clinical follow-up
• Patients with the following hematologic/biochemical values:

• Absolute Neutrophil Count ANC > 1500/µl.
• Platelets > 100.000 /µl.
• Hemoglobine > 10 g/dl.
• Bilirrubin < 1.5 mg/dl.
• Aspartate aminotransfereasa (AST) and Alanine transaminase (ALT) ≤ 3 x LSN, except in case of hepatic metastases: upper 5 x LSN
• Creatinine clearance ≥ 45 ml/min.

Exclusion criteria

• Previous treatment for advanced disease. Chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neadjuvant treatment
• history of haemoptysis (defined as at least half a teaspoon's emission of red blood) in the 3 months prior to inclusion
• evidence by CT of tumor cavitations, or tumours invading or abutting major blood vessels
• Known or suspected brain metastases non-treated.
• Major surgery within 28 days of starting treatment.
• Minor surgery within 24 hours before starting the treatment.
• Non-controlled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg).
• Patients with coronary disease or uncontrolled arrhytmia, uncontrolled cerebrovascular disease and other clinical conditions that, in judgment of the investigator, contraindicate the patient's participation in the study.
• History or evidence of bleeding diathesis or hereditary coagulopathy.
• Contraindication or suspected allergy to the products under investigation in the study:: paclitaxel, carboplatine or bevacizumab.
• Patients who are pregnant or breasfeeding. Women of childbearing potencial must have a negative pregnancy test performed within 7 days before the onset of treatment.
• Substance abuse of clinical, psychological or social conditions that can undermine the validity of the informed consent or protocol compliance